EGFR and non-small cell lung carcinoma: The third-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) has become the standard therapy for advanced EGFR-mutated NSCLC due to its dual inhibitory effect on sensitive EGFR mutations and T790M resistance mutations (3).